DICE Therapeutics
Meina joined DICE Therapeutics in late Jan 2021 as Vice President of Development Sciences. Prior to DICE, Meina was a Principal Scientist and a therapeutic area lead for autoimmune/inflammatory diseases in the Clinical Pharmacology organization at Genentech, a member of the Roche Group. Prior to joining Genentech in 2009, Meina was Director of PK/PD at PDL Biopharma (later spin off as “Facet Biotech, Corp” and acquired by AbbVie) where she established and managed the PK/PD department after joining the company in 1998.
Over her 22 years of drug development industry experience, Meina was involved as the lead clinical pharmacologist and/or the pharmacology teamleader, in both nonclinical and clinical development of 20+ molecules (including mAbs, F’ab, fusion proteins and small molecule drugs), primarily in autoimmune or inflammatory disease areas, including Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Rheumatoid Arthritis, Lupus, and Asthma.
Meina completed her 3+ years post-doctoral fellowship at Harvard Medical School and holds a Ph.D degree in Physiology from East Tennessee State University.
This person is not in the org chart
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.